1348 related articles for article (PubMed ID: 20083659)
1. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
2. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
4. Quantitative methods for developing Fc mutants with extended half-lives.
Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
[TBL] [Abstract][Full Text] [Related]
5. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
[TBL] [Abstract][Full Text] [Related]
6. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
[TBL] [Abstract][Full Text] [Related]
7. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
8. Development of new models for the analysis of Fc-FcRn interactions.
Gurbaxani BM; Morrison SL
Mol Immunol; 2006 Mar; 43(9):1379-89. PubMed ID: 16183124
[TBL] [Abstract][Full Text] [Related]
9. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization of a human Fc fragment engineered for extended serum half-life.
Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
[TBL] [Abstract][Full Text] [Related]
11. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
12. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
15. FcRn mediates elongated serum half-life of human IgG in cattle.
Kacskovics I; Kis Z; Mayer B; West AP; Tiangco NE; Tilahun M; Cervenak L; Bjorkman PJ; Goldsby RA; Szenci O; Hammarström L
Int Immunol; 2006 Apr; 18(4):525-36. PubMed ID: 16481343
[TBL] [Abstract][Full Text] [Related]
16. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
Andersen JT; Daba MB; Sandlie I
Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
[TBL] [Abstract][Full Text] [Related]
17. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
18. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.
Ghetie V; Hubbard JG; Kim JK; Tsen MF; Lee Y; Ward ES
Eur J Immunol; 1996 Mar; 26(3):690-6. PubMed ID: 8605939
[TBL] [Abstract][Full Text] [Related]
19. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
20. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
